Tag: Holkira Pak

CATIE HepCinfo Update 7.8

Holkira Pak is now indicated for people with HIV/Hep C co-infection or post liver transplant The Holkira Pak product monograph has been updated to include that people who are co-infected with HIV and Hep C or who have had a liver transplant can be treated with this drug combination. Holkira Pak is a combination of… Read more »

CATIE’s HepCinfo Update 6.20

New and Noteworthy High cure rates for people on opiate substitution therapy with Holkira Pak A small, mid-stage clinical trial of participants on opioid substitution therapy (OST) who took Holkira Pak and ribavirin for 12 weeks had a cure rate of 97% reported researchers in the Journal of Hepatology. OST is taken by people who… Read more »

CATIE HepCinfo Update 6.17

New and Noteworthy Daclatasvir approved in Canada The Hep C drug daclatasvir (Daklinza) has been approved in Canada for people with genotype 1 or 2 virus. It has also been conditionally approved for people with genotype 3 virus pending the outcome of a late-stage clinical trial. Daclatasvir is taken with sofosbuvir (Sovaldi) for 12 weeks… Read more »

CTAC Resource – Harvoni & Holkira Pak coverage in Canada

CTAC is pleased to share with you a preview of the treatment access information that will be contained in our soon to be launched Treatment Access Map (TxMAP).  Using data pulled from the TxMAP database we have created this one-page resource that outlines the public drug coverage under provincial and territorial formularies for Harvoni and… Read more »

CATIE’s HepCInfo Update 6.13

New and Noteworthy Holkira Pak added to formulary in Ontario Increasing Hep C treatment could halve Hep C transmission in U.K. gay men over 10 years Statins linked to lower risk of liver failure and death in people with Hep C Holkira Pak added to formulary in Ontario Holkira Pak has been added to the… Read more »